De Rosa P, Severi F, Zadran S, Russo M, Aloisi S, Rigamonti A, et al. MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. Int J Mol Sci. 2023;24: pubmed publisher

Koch J, Schober S, Hindupur S, Sch xf6 ning C, Klein F, Mantwill K, et al. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. Nat Commun. 2022;13:4689 pubmed publisher

Yang W, Jiang X, Zhao X, Mao P. Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor. Kaohsiung J Med Sci. 2021;: pubmed publisher

Kuganesan N, Dlamini S, Tillekeratne L, Taylor W. Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. J Biol Chem. 2021;297:101365 pubmed publisher

Bollaert E, Johanns M, Herinckx G, de Rocca Serra A, Vandewalle V, Havelange V, et al. HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation. Cell Signal. 2018;44:158-170 pubmed publisher

Narasimha A, Kaulich M, Shapiro G, Choi Y, Sicinski P, Dowdy S. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. elife. 2014;3: pubmed publisher